Fate Therapeutics Adds Pratik Multani, M.D., M.S., as Vice President Clinical Development...

Fate Therapeutics Adds Pratik Multani, M.D., M.S., as Vice President Clinical
Development to Advance Upcoming Clinical Programs of Stem Cell Modulators

LA JOLLA, Calif., May 18 /PRNewswire/ -- Fate Therapeutics, Inc. announced
today that it has further expanded the Company's executive team with the
addition of Pratik Multani, M.D., M.S., as Vice President of Clinical
Development. With more than a decade of clinical development experience, Dr.
Multani will lead Fate Therapeutics' upcoming clinical trials of Stem Cell
Modulators (SCMs), small molecules and biologics that guide cell fate for
therapeutic purposes. SCMs can potentially be applied in many areas,
including regenerative medicine, hematological diseases, metastatic cancer,
traumatic injury and degenerative diseases.

"Fate Therapeutics has been singularly focused on interrogating adult stem
cell and induced pluripotent stem cell biology to find small molecule and
biologic drug candidates that can modulate cell fate to develop tomorrow's
medicines," said Paul Grayson, President and CEO of Fate Therapeutics. "As we
are rapidly preparing to advance the Company's first drug candidate into
clinical trials, Dr. Multani's successful clinical development experience and
distinguished medical training will be a tremendous asset to drive our
clinical programs forward."

Fate Therapeutics is utilizing its adult stem cell biology engine and induced
pluripotent stem (iPS) cell technology platform to develop SCMs that can
direct adult stem cell proliferation and function. Adult stem cells are
naturally-occurring cells found in almost all tissues or organs in the body
and are primarily responsible for maintaining and repairing their native
tissue. An adult stem cell has unique properties, in that it can renew itself
and differentiate to become some or all of the major specialized cell types of
the particular tissue or organ in which it is found. The discovery of a
number of conserved mechanisms from developmental biology and tissue repair
has led to the identification of small molecules and biologics that can direct
stem cell proliferation and function. Fate Therapeutics is developing these
small molecule and biologic SCMs to modulate the activity of adult stem cells
to stimulate healing or block cancer growth.

"Fate's distinct and unique approach of using small molecules and biologics in
stem cell medicine provides a well-defined regulatory path and allows the
Company to move quickly into clinical programs to ultimately meet the needs of
patients," said Dr. Multani. "This role represents to me one of the most
exciting in the industry as we are applying the power of small molecule and
biologic drug development, where we can use clearly defined safety and
efficacy endpoints, to the revolutionary field of stem cell biology in order
to develop new medicines for diseases and conditions that currently have
limited to no treatment options."

Prior to joining Fate Therapeutics, Dr. Multani was Vice President of
Translational Medicine at Kalypsys, Inc. since 2007, where he advanced the
development of multiple compounds in the therapeutic areas of pain and
inflammation and metabolic diseases. From 2005 to 2007 as Senior Vice
President of Clinical Development and then Chief Medical Officer at Kanisa
Pharmaceuticals, Dr. Multani led the clinical development of zosuquidar as
well as a companion diagnostic in acute myeloid leukemia. From 2004 to 2005
as Vice President of Clinical Development at Salmedix, he led three clinical
development programs in hematologic malignancies and solid tumors. From 1999
to 2004 advancing from Associate Director of Oncology and Hematology to Senior
Director of Medical Research at Biogen-Idec, Dr. Multani led or provided
strategic direction for multiple drug development programs in Phase 1 to Phase
4 clinical trials, including Zevalin(R) and Rituxan(R).

Before his career in industry, Dr. Multani held academic and clinical
positions as an instructor in medicine at Harvard Medical School and assistant
in medicine at Massachusetts General Hospital. His postdoctoral training
includes a fellowship in hematology and oncology at Dana-Farber/Partners and
an internship and residency in Internal Medicine at Massachusetts General
Hospital. Dr. Multani received his M.S. in clinical epidemiology from Harvard
School of Public Health, his M.D. from Harvard Medical School, and he
graduated summa cum laude from Yale University with a B.S. in chemistry and
biology.

About Fate Therapeutics, Inc.
Fate Therapeutics is interrogating adult stem cell biology and applying
induced pluripotent stem (iPS) cell technology to develop Stem Cell Modulators
(SCMs), small molecule or biologic compounds that guide cell fate for
therapeutic purposes. Fate's approach has broad therapeutic potential in
areas such as regenerative medicine, hematological diseases, metastatic
cancer, traumatic injury and degenerative diseases. The Company's first
therapeutic candidate is scheduled to enter clinical trials in early 2009 in
hematopoietic stem cell support. In addition, Fate Therapeutics and Stemgent
have formed an alliance - Catalyst - a collaborative program to provide its
partners with first access to the most advanced induced pluripotent stem (iPS)
cell technologies for drug discovery and development. Fate Therapeutics is
headquartered in La Jolla, CA. For more information, please visit
http://www.fatetherapeutics.com.

Fate Therapeutics along with Stemgent, Genzyme, Burrill & Company and WIRED
Magazine, will be featured in a panel presentation entitled "Mastering Your
(Cell) Fate: Stem Cells, iPSCs and the Future of Medicine" on May 18, 2009 at
2 p.m. at the 2009 BIO International Convention in Atlanta, GA.

SOURCE Fate Therapeutics, Inc.

Cory Tromblee of MacDougall Biomedical Communications, +1-781-235-3060,
ctromblee@macbiocom.com, for Fate Therapeutics, Inc.